Carboxypeptidases A1 and A2 from the perfusate of rat mesenteric arterial bed differentially process angiotensin peptides  by Pereira, Hugo J.V. et al.
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Here  we  report  the  isolation  of  carboxypeptidases  A1  and  A2 (CPA1  and  CPA2)  from  the  rat  mesenteric
arterial  bed  perfusate,  which  were  found  to be identical  with  their  pancreatic  counterparts.  Angiotensin
(Ang)  I, Ang  II, Ang-(1-9)  and  Ang-(1-12)  were  differentially  processed  by  these  enzymes,  worthy  men-
tioning  the  peculiar  CPA1-catalyzed  conversion  of Ang  II to  Ang-(1-7)  and  the  CPA2-mediated  formation
of  Ang  I from  Ang-(1-12).  We  detected  gene  transcripts  for CPA1  and  CPA2 in  mesentery  and  othereywords:
arboxypeptidase
ngiotensin I
ngiotensin II
ngiotensin-(1-7)
ngiotensin-(1-12)
extrapancreatic  tissues,  indicating  that  these  CPAs  might  play  a role  in  the  renin–angiotensin  system  in
addition  to their functions  as  digestive  enzymes.
© 2011  Elsevier  Inc.  Open access under the Elsevier OA license.CE2
. Introduction
The renin–angiotensin system (RAS) consists of a number of
eptide ligands and receptors whose distributions vary between
pecies and, within species between individuals, according to the
evelopmental stage, integrity and functional status of their dif-
erent tissues. Such complexity reﬂects the many physiological
nd physiopathological functions carried out by the RAS which, in
ddition, require a network of intertwined enzymatic pathways to
roduce the different angiotensin (Ang) peptides that act as effec-
or molecules of the system. At ﬁrst the RAS was thought as a
ypical endocrine system in which the effector hormone Ang II
ould be formed by a two-step reaction, whereby the Ang I ini-
ially released from angiotensinogen by circulating renin would
hen be converted into Ang II by the action of the metalloprotease
ngiotensin converting enzyme (ACE). Despite the central role of
his angiotensinogen–renin-ACE-Ang II axis for many of the func-
ions carried out by the RAS, it became clear over the years that
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Open access under the Elsevier OA license.in some tissues Ang II could also be formed from Ang I by ACE-
independent [5] or from Ang-(1-12) by renin-independent [20]
pathways. The serine protease chymase, for instance, is the major
enzyme that converts Ang I to Ang II in the human heart [32], while
in the rat heart infused with Ang-(1-12) this enzyme appears to
be responsible for most of the hemodynamic effects caused by
the released Ang II [26]. Moreover, several Ang peptides shorter
than Ang II were described as functionally active components of
the RAS [9],  implying the participation of proteases other than ACE
to account for the required processing of the respective Ang pre-
cursors. Among these, neprilysin generates C-terminally modiﬁed
Ang fragments, releasing Ang-(1-7) from both Ang I and Ang-(1-
9) [28]. A variety of enzymes displaying CPA-like activity have
also been implicated in the proteolytic processing of Ang peptides.
Cathepsin A of human heart generates Ang-(1-7) and Ang-(1-9),
two molecules that act as bradykinin potentiator and ACE inhibitor,
respectively [12]. Besides, in the human heart a mast cell CPA-like
enzyme has been proposed to regulate the local Ang II formation
by releasing the ACE inhibitor Ang-(1-9) into the interstitial ﬂuid
[13]. In porcine kidney, cathepsin A seems to participate in the local
RAS by forming Ang-(1-9) and Ang II, but not Ang-(1-7) [19]. The
identiﬁcation of ACE2 by genomic approaches as a human homolog
of ACE that displays carboxypeptidase activity [6,30] reinforces the
current awareness of the functional complexity of the multifaceted,
multicomponent RAS. ACE2 can act upon Ang I and Ang II to gen-
erate Ang-(1-9) and Ang-(1-7), respectively, two  metabolites that
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at room temperature to remove any potential genomic DNA con-8 H.J.V. Pereira et al. / 
ppose the action of Ang II either by regulating the formation of Ang
I by ACE [13,29] or triggering opposing biological responses medi-
ted by distinct receptors [7].  In previous investigations we  showed
hat the perfused ex vivo preparation of the rat mesenteric arterial
ed (MAB), known as the McGregor’s preparation [18], secretes a
ultiplicity of Ang I- and Ang II-processing CPs potentially rele-
ant to the metabolism of vasoactive and other peptides in the rat
esentery [22,25]. To further characterize these enzymes, in the
resent study we aimed at: (1) identifying the CPs that constitute
ajor Ang processing pathways in the rat MAB  perfusate; (2) inves-
igating the enzymatic activities of puriﬁed CPs obtained from rat
AB  perfusate toward Ang I, Ang-(1-9), Ang II and Ang-(1-12); and
3) determining the expression proﬁle of the mRNAs for the differ-
nt CPAs in representative rat tissues, in which RAS is believed to
lay a functional role in the local circulatory system.
. Material and methods
.1. Material
Potato carboxypeptidase inhibitor (PCI), N-carbobenzyloxy-
al-Phe (Z-Val-Phe), Ang I (Asp1-Arg-Val-Tyr-Ile-His-Pro-Phe-His-
eu10), Ang II (Asp1-Arg-Val-Tyr-Ile-His-Pro-Phe8), bradykinin (BK;
rg1-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg9), dl-2-mercaptomethyl-
-guanidinoethylthiopropanoic acid (MGTA),1,10-phenanthroline,
oybean trypsin inhibitor (SBTI) and DEAE-Sepharose fast ﬂow
ere obtained from Sigma Chemical Co. (St. Louis, MO). Ang-(1-
) and Ang-(1-12) were synthesized by conventional Fmoc solid
hase peptide synthesis [8] and puriﬁed by C-18 reversed-phase
PLC. Packed MonoQ 5/5 column was from Pharmacia Fine Chem-
cals (Uppsala, Sweden). All other reagents used were of analytical
rade.
.2. Isolation of the rat mesentery and harvesting of MAB
erfusate
All animal protocols were approved by the School of Medicine of
ibeirão Preto Institutional Animal Care and Use Committees. The
urgical procedures for the isolation of the rat mesentery and the
erfusion of the respective arterial system with Krebs solution were
erformed as previously described [24]. High molecular mass sub-
tances of pooled rat MAB  perfusates were concentrated 80-fold by
ltraﬁltration under N2 pressure using Amicon YM-10 membrane
nd stored at 4 ◦C until use.
.3. Enzyme assays
All rat MAB  CPA assays were carried out at 37 ◦C by incubat-
ng the speciﬁed substrate with the enzyme in 150 L of 20 mM
ris–HCl buffer pH 8.1, and the reactions terminated by the addition
f 10 L of 5% TFA. One unit of enzyme activity was  deﬁned as the
mount of enzyme capable of releasing 1.0 mol  of product per min
rom the indicated substrate solution; unless otherwise speciﬁed,
he concentration of Z-Val-Phe in the reaction mixture was 10 mM
nd those of angiotensin peptides and bradykinin were 0.25 mM.
he cleavage of Z-Val-Phe and other peptides was assessed by
eversed-phase HPLC analysis on a Shimadzu SCL-6B equipment
tted with a 0.46 cm × 15 cm Vydac ODS column; Phe and peptide
ragments were eluted with a linear gradient of acetonitrile concen-
ration ranging from 0 to 10% (10 min) and 12 to 45% (33 min) in
.1% TFA, respectively, at a ﬂow rate of 1.0 mL/min, and monitored
y absorbance at 215 nm;  peptides were identiﬁed by comparison
f their retention times with those of the respective cognate syn-
hetic peptides. Whenever used, the protease inhibitors MGTA, PCI,
,10-phenanthroline and SBTI were preincubated for 10 min, at the
ndicated concentrations, with the enzyme solution.es 33 (2012) 67–76
2.3.1. Estimation of kinetic constants
To estimate the kinetic parameters for the rat CPA1 and CPA2-
catalyzed hydrolyses of Ang II, initial velocities were determined, in
duplicate, under conditions adjusted to limit substrate consump-
tion to less than 10% of its initial concentration. Thus, samples of
rat MAB  CPA1 (0.45 mU,  based on Z-Val-Phe hydrolysis) and CPA2
(9.2 mU,  based on Z-Val-Phe hydrolysis) were incubated at 37 ◦C
for 20 min  and 150 min, respectively, in a ﬁnal volume of 0.5 mL
of 20 mM Tris–HCl buffer, pH 8.1, with seven concentrations of
Ang II ranging from 10 to 200 M for CPA1 and 25 to 500 M for
CPA2. Reactions were terminated by the addition of 20 L of 5% TFA
and the respective products were assayed by HPLC analysis. The
kinetic parameters Michaelis constant, Km, and catalytic constant,
kcat, were derived from initial velocity data (N = 2) using GraFit
version 3.0 software [15], which performed non-linear regres-
sion analysis of data plotted according to the Michaelis–Menten
equation.
2.4. Enzyme puriﬁcation
The initial step in the puriﬁcation of the two  major rat MAB  Ang-
processing carboxypeptidases was carried out by anion exchange
chromatography, as detailed in a previous work [25]. Further puriﬁ-
cation leading to the isolation of CPA1 and CPA2 was achieved
by chromatographing the major Ang-(1-7)-forming enzyme and
the most conspicuous Ang-(1-9)-forming enzyme of the rat MAB
perfusate [25], respectively, over MonoQ 5/5 column; each chro-
matography was developed at room temperature with a ﬂow
rate of 6 mL/h using 20 mL  of the indicated linear gradient of
NaCl concentration in 20 mM  Tris–HCl buffer, pH 8.1. Enzyme
activity was measured using either Z-Val-Phe or Ang II as the
substrate, as indicated in the respective ﬁgures. Contaminant
kininase activity was  removed from pooled CPA-containing frac-
tions by afﬁnity chromatography over arginine-Sepharose column
(1.5 cm × 3.5 cm)  equilibrated and developed with 1 M NaCl solu-
tion buffered with 30 mM Tris–HCl, pH 7.2, as previously described
[23]. The CPA-containing fractions were pooled and stored at 4 ◦C
until use.
2.5. SDS-PAGE
Analytical SDS-PAGE was carried out on 15% polyacrylamide
gels essentially as described [14], using a Mini-Protean 3 elec-
trophoresis system (BioRad, Hercules, CA, USA). The Mr  standard
proteins (14.4–116 kDa) were from Fermentas Inc. (Hoover, MD,
USA); protein bands were stained with Coomassie Blue R-250. SDS-
PAGE separations intended for preparing proteins to be digested
in-gel and further characterized by LC–MS/MS were performed on
precast 4–12% gradient polyacrylamide gels using an Invitrogen
NuPage system (Carlsbad, CA, USA). Proteins bands were stained
with Coomassie Blue G-250.
2.6. RNA extraction and reverse transcriptase-polymerase chain
reaction (RT-PCR)
Total RNA was extracted from rat mesentery, pancreas, kid-
ney, liver, lung, heart, aorta and carotid using the Trizol reagent
in RNAse-free labware, following the manufacturer instructions
(Invitrogen, Carlsbad, CA, USA). RNA integrity was conﬁrmed by
agarose gel electrophoresis and then treated with DNAse for 15 mintamination. Four micrograms of total RNA from each tissue, based
on A260 nm measurements, and oligo-d(T) were used to generate
cDNAs by reverse transcription following SuperScript II protocols
(Invitrogen).
H.J.V. Pereira et al. / Peptid
Table  1
Rat-speciﬁc oligonucleotide primers used for RT-PCR.
Primer Sequence (5′ → 3′)
CPA1 (sense) ggggatccatgaagagactactg
CPA1 (antisense) ggctcgagtcagtaggggtgtttg
CPA2 (sense) gggtcgacttatgaggttgaccctgttattg
CPA2 (antisense) ggcggccgctcactaataggggtggtctcg
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MonoQ anion-exchange chromatography from freshly prepared
material analogous to that described as P4 in previous work
[25]. This chromatographic step resulted in the puriﬁcation of an
enzyme to apparent homogeneity as judged by its migration during
Fig. 1. Puriﬁcation of CPA1 from the perfusate of rat MAB  by MonoQ anion exchange
chromatography. (A) The sample loaded onto the column, prepared essentially as
described in Fig. 2, peak 4 [25], was  the fraction of the perfusate that contained
the major Ang-(1-7)-forming enzyme of pooled material from four isolated MABs.
The MonoQ column was equilibrated at room temperature with 20 mM Tris–HCl
buffer, pH 8.1, and developed with 10 column volumes of a linear gradient of NaCl
concentration (20–250 mM)  in equilibrating buffer, at ﬂow rate of 6 mL/min. Protein
concentrations of the resulting fractions were estimated by A280 nm measurements
and  the respective enzymatic activities were assayed with Ang II as the substrate.
The yield of this puriﬁcation step was 84%, based on the recovery of the Ang-(1-
7)-forming activity. (B) SDS-PAGE analysis of samples of whole rat MAB  perfusate
(lane 1), material loaded onto the MonoQ column (lane 2) and MonoQ-puriﬁed Ang--Actin (sense) ctaaggcaaaccgtgaaaaga
-Actin (antisense) attgccgatagtgatgacctg
.6.1. Analysis of CPA transcript expression in different tissues
Each PCR reaction was performed in a total volume of 50 L,
ontaining 5 pmol of the respective set of primers (Table 1), PCR
uffer (20 mM Tris–HCl, pH 8.4; 50 mM KCl; 1.0 mM MgCl2), 0.1 mM
NTPs and 2.5 U of recombinant Taq DNA polymerase (Invitrogen).
ycling conditions consisted of an initial denaturation period of
 min  at 94 ◦C, followed by 40 three-step ampliﬁcation cycles of
 min  denaturation at 94 ◦C, 1 min  annealing carried out at 55 ◦C,
0 ◦C and 45 ◦C for CPA1, CPA2 and -actin, respectively, terminat-
ng with an extension at 72 ◦C for 1.5 min. Samples were incubated
or additional 30 min  period at 72 ◦C (terminal elongation) after
ompletion of the ﬁnal cycle. For each set of primers, RT-PCR was
erformed on sterile water and RNA to check for contamination.
liquots of 10 L of each PCR product were run on a 1% agarose
el, stained with ethidium bromide and subjected to densitomet-
ic scanning by ImageJ software (http://rsb.info.nih.gov/ij/); the
ntensity of each particular DNA was normalized to the respective
-actin PCR product and used as a measure of transcript expression.
.6.2. Cloning and sequencing
The cloning and sequencing of cDNAs encoding CPA1 and CPA2
ere carried out only with material derived from rat mesentery,
he tissue from which we isolated the enzymes studied in the
resent work. The RNA extraction and RT were done as described
n Section 2.6.  The PCR reaction was performed using the Taq
iFi DNA polymerase (Invitrogen) using temperature cycling as
escribed in Section 2.6.1. After PCR ampliﬁcation the products
ere puriﬁed from the agarose gel using a DNA extraction kit (Fer-
entas) as instructed by the manufacturer. Puriﬁed PCR products
rom rat mesentery were inserted into a plasmid vector accord-
ng to the manufacturer’s instructions (TOPO TA Cloning® Version
2, Invitrogen). Plasmids were transfected into Escherichia coli
nd the positive clones were identiﬁed after DNA digestion with
peciﬁc restriction enzymes, Bam HI and XhoI for CPA1 and Sal
 and Not I for CPA2. The digestion products were analyzed by
garose gel as described in Section 2.6.1 and the plasmids of the
elected clones were puriﬁed (Promega, Madison, USA). Sequenc-
ng of 500 ng of DNA was done in both directions by the BigDye
erminator chemistry with an ABI 3100 Genetic Analyzer (Applied
iosystems, Foster City, CA) using M13  Forward and M13 Reverse
rimers. Sequence similarities between each individual rat mesen-
eric CPA and other known proteins were searched using the BLAST
rogram (http://www.ncbi.nlm.nih.gov/blast/).
.7. Protein identiﬁcation by tandem mass spectrometry
The bands of interest of SDS-PAGE gels were excised and the
roteins therein were reduced, alkylated and digested in-gel with
rypsin. LC–MS/MS experiments to identify the peptides of indi-
idual digestion mixtures were performed at the Tufts University
ore Facility on a Thermo LTQ ion trap mass spectrometer after
eparation of peptides on C18 column and microelectrospray ion-
zation. The instrument was set at needle voltage of 3 kV, resolution
f 3 Da, collision energy of 30% and recurring ions were excluded.
C–MS/MS data were searched against the NCBI non-redundantes 33 (2012) 67–76 69
protein database (ftp://ftp.ncbi.nih.gov/blast/db/FASTA/nr)  using
the SEQUEST algorithm for protein identiﬁcation.
3. Results
3.1. Isolation and structural characterization of two major rat
MAB perfusate carboxypeptidases A
We  have previously shown that rat MAB  perfusate contains ﬁve
Ang-processing CPAs that are distinguishable by their chromato-
graphic behavior, substrate speciﬁcity and sensitivity to inhibitors
[25]. Two of these enzymes were chosen to be further character-
ized in the present work as major representatives of Ang I and Ang
II-processing activities of the rat MAB  perfusate.
3.1.1. Isolation of the rat MAB  perfusate CPA1
As shown in Fig. 1A, an Ang-(1-7)-forming CPA was isolated by(1-7)-forming enzyme (lane 3) on 15% polyacrylamide gel stained with coomassie
blue; the positions of Mr  standard proteins (14.4–116 kDa) are indicated on the left
side  of the gel. The identiﬁcation of the major Ang-(1-7)-forming enzyme of the rat
MAB  perfusate as CPA1 was done as shown in Fig. 2.
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Met Lys Arg Leu Leu Ile Leu Ser Leu  Leu Leu Glu Ala Val Cys Gly As n Glu Asn Phe  20 
ATG AAG AGA CTA CTG ATT CTG AGT CTG CTG CTG GAA GCA GTC TGT GGC AAT GAG AAC TTT 60' 
Val Gly His Gln Val Leu Arg Ile  Ser Ala Ala Asp Glu Ala Gln Va l Gln Lys Val Lys  40 
GTG GGA CAC CAG GTT CTC CGA ATC TCT GCA GCC GAT GAA GCC CAG GTG CAG AAA GTG AAG 120' 
Glu Leu Glu Asp Leu Glu His Leu  Gln Leu Asp Phe Trp Arg Asp Al a Ala Arg Ala Gly  60 
GAG TTG GAG GAC CTG GAG CAC TTG CAG TTG GAC TTC TGG CGG GAC GCT GCC CGG GCC GGT 180' 
Ile Pro Ile Asp Val Arg Val Pro  Phe Pro Ser Ile Gln Ser Val Ly s Ala Phe Leu Glu  80 
ATC CCC ATT GAT GTC AGA GTG CCC TTC CCC AGC ATC CAA TCT GTG AAA GCA TTC TTG GAA 240' 
Tyr His Gly Ile Ser Tyr Glu Ile  Met Ile Glu Asp Val Gln Leu Le u Leu Asp Glu Glu  100 
TAT CAT GGT ATT AGC TAT GAG ATC ATG ATT GAA GAT GTG CAG TTA CTG CTC GAT GAG GAG 300' 
Lys Gln Gln Met Ser Ala Phe Gln  Ala Arg Ala Leu Ser Thr Asp Se r Phe Asn Tyr Ala  120 
AAA CA G CAG ATG TCT GCC TTC CAG GCC  AGG GCC TTG TCC ACT GAC TC T TTC AAT TAT GCC  360' 
Thr Tyr His Thr Leu Asp Glu Ile  Tyr Glu Phe Met Asp Leu Leu Val Al a Glu His Pro 140 
ACC TAT CAT ACG CTG GAT GAG ATC TAC GAA TTC ATG GAC CTG CTG GTG GCT GAG CAC CCA 420' 
Gln Leu Val Ser Lys Ile Gln Ile  Gly Asn Thr Phe Glu Gly Arg Pro Il e His Val Leu 160 
CAG CTT GTG AGC AAG ATC CAG ATC GGC AAC ACC TTT GAA GGT CGC CCC ATC CAT GTG CTG 480' 
Lys Phe Ser Thr Gly Gly Thr Asn  Arg Pro Ala Ile Trp Ile Asp Thr Gl y Ile His Ser 180 
AAG TTC AGC ACT GGA GGG ACC AAT CGC CCA GCA ATC TGG ATC GAC ACT GGC ATC CAT TCT 540' 
Arg Glu Trp Val Thr Gln Ala Ser Gly  Val Trp Phe Ala Lys Lys Ile Th r Lys Asp Tyr 200 
AGG GAG TGG GTC ACC CAG GCT AGT GGG GTC TGG TTT GCA AAG AAG ATC ACC AAA GAC TAT 600' 
Gly Gln Asp Thr Thr Phe Thr Ala Val  Leu Asp Asn Met Asp Ile Phe Le u Glu Ile Val 220 
GGC CAG GAC CCC ACC TTC ACA GCC GTT CTT GAC AAC ATG GAC ATC TTC TTG GAG ATT GTC  660' 
Thr Asn Pro Asp Gly Phe Ala Tyr Thr  His Lys Thr Asn Arg Met Trp Ar g Lys Thr Arg 240 
ACC AAC CCT GAT GGT TTT GCC TAC ACC  CAC AAA ACG AAT CGC ATG TGG CG C AAG ACT CGA  720' 
Ser Hi s Thr Gln Gly Ser Leu Cys  Val Gly Val Asp Pro Asn Arg As n Trp Asp Ala Gly  260 
TCA CAC ACC CAG GGC TCC CTC TGT GTT GGT GTG GAC CCC AAC AGG AAC TGG GAC GCT GGC 780' 
Phe Gly Met Ala Gly Ala Ser Ser  Asn Pro Cys Ser Glu Thr Tyr Ar g Gl y Lys Phe Pro 280 
TTT GGG ATG GCC GGA GCA AGT AGC AAC CCC TGC TCG GAA ACT TAC CGA GGC AAA TTT CCC 840' 
Asn Ser Glu Val Glu Val Lys Ser Ile  Val Asp Phe Val Thr Ser Hi s Gly Asn Ile Lys  300 
AAC TCT GAG GTG GAG GTC AAG TCC ATC  GTG GAC TTT GTG ACG AGC CAT GGG AAC ATC AAG 900' 
Ala Phe Ile Ser Ile His Ser Tyr  Ser Gln Leu Leu Leu Tyr Pro Tyr Gl y Tyr Thr Ser 320 
GCC TTC ATC TCC ATC CAC AGC TAT TCC CAG CTC CTG CTC TAC CCC TAC GGC TAC ACG TCG 960' 
Glu Pro Ala Pro Asp Gln Ala Glu  Leu Asp Gln Leu Ala Lys Ser Ala Va l Thr Ala Leu 340 
GAA CCA GCC CCT GAC CAG GCA GAG CTG GAT CAG CTA GCT AAG TCT GCT GTG ACA GCC TTG 1020'
Thr Ser Leu His Gly Thr Lys Phe Lys  Tyr Gly Ser Ile Ile Asp Thr Il e Tyr Gln Ala 360 
ACG TCT CTA CAC GGG ACC AAG TTC AAG TAT GGC AGC ATC ATC GAT ACA ATC TAT CAA GCC 1080'
Ser Gly Ser Thr Ile Asp Trp Thr Tyr  Ser Gln Gly Ile Lys Tyr Ser Ph e Thr Phe Glu 380 
AGT GGG AGC ACT ATC GAT TGG ACC TAC AGC CAG GGC ATC AAG TAC TCT TTC ACT TTT GAA 1140'
Leu Arg Asp Thr Gly Leu Arg Gly Phe  Leu Leu Pro Ala Ser Gln Ile Il e Pro Thr Ala  400 
CTG AGG GAC ACT GGG CTT AGA GGA TTC CTG CTG CCT GCC TCC CAG ATC ATC CCT ACG GCG 1200'
Glu Glu Thr Trp Leu Ala Leu Leu  Thr Ile Met Asp His Thr Val Ly s His Pro Tyr stop 419 
GAG GAG ACA TGG CTG GCC CTT TTG ACC ATC ATG GAC CAC ACA GTC AAA CAC CCC TAC TGA 1260'
Fig. 2. Partial nucleotide sequence of the cDNA encoding the rat mesenteric preproCPA1 and amino acid sequences of peptides derived from the major Ang-(1-7)-forming
enzyme of the rat MAB  perfusate. The sequences of the rat pancreatic preproCPA1 cDNA [27] (nucleotides 1–1260, primed numerals) and of the deduced amino acid sequence
for  the rat pancreatic preproCPA1 [27] (residues 1–419; NCBI GenBank ID: NP 058694.2) are shown for comparison. Sequence identity between the two polynucleotide chains
is  indicated by underlined bases in the pancreatic preproCPA1 cDNA sequence; note that the analogous nucleotide sequence comprising the segment between T650 and
A723  of the pancreatic preproCPA1 cDNA has not been determined for the mesenteric cDNA. A single base change, C876T, corresponding to a silent mutation involving Ile289,
i Gly277
a tion o
b
S
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f
7
M
ts  the only difference observed between the two  sequences. The tryptic fragments 
mino acid sequence of the pancreatic preproCPA1, were generated by in-gel diges
y  de novo peptide sequencing via tandem mass spectrometry.
DS-PAGE as a single component of molecular mass ca. 34 kDa
Fig. 1B). This molecular mass value is consistent with that of
he rat pancreatic CPA1 [27], a protein whose sequence was also
hown to contain segments which fully match those of tryptic
ragments derived from the puriﬁed rat MAB  perfusate Ang-(1-
)-forming CPA (Fig. 2). The ﬁnding of such an active CPA1 in rat
AB  perfusate, similar to the pancreatic enzyme, prompted us
o investigate the existence and properties of the respective RNA-Lys287, Phe279-Lys287 and Ser335-Lys347, indicated by boldface residues within the
f the major Ang-(1-7)-forming enzyme of the rat MAB  perfusate and characterized
message in the mesentery to broaden the comparison between the
enzymes isolated from each of these tissues. The partial sequence
of the cloned cDNA for the rat mesenteric enzyme was  obtained
as described in Section 2.6.2, resulting in a nucleotide sequence
that shows correspondence between its deducible amino acid
sequence and that of the rat pancreatic CPA1 [27] for all positions
amenable to comparison in the alignment of Fig. 2. Comparative
analysis of cDNA sequences for rat CPA1 derived from pancreas
Peptides 33 (2012) 67–76 71
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Fig. 3. Puriﬁcation of CPA2 from the perfusate of rat MAB  by MonoQ anion exchange
chromatography. (A) The sample loaded onto the MonoQ column, prepared essen-
tially as described in Fig. 2, peak 3 [25], was the fraction of the perfusate that
contained the major Ang-(1-9)-forming enzyme of pooled material from four iso-
lated MABs. The column was equilibrated at room temperature with 20 mM Tris–HCl
buffer, pH 8.1, and developed with 10 column volumes of a linear gradient of NaCl
concentration (20–120 mM)  in equilibrating buffer, at ﬂow rate of 6 mL/min. Protein
concentrations of the resulting fractions were estimated by A280 nm measurements
and  the respective enzymatic activities were assayed with Ang II as the substrate.
The yield of this puriﬁcation step was 55%, based on the recovery of the Z-Val-Phe-
hydrolyzing activity. (B) The MonoQ-puriﬁed Ang-(1-9)-forming enzyme was  rid
of  contaminating kininase by passage through arginine-Sepharose column equili-
brated and developed with 30 mM Tris–HCl buffer, pH 7.2, containing 1.0 M NaCl;
yield of 98% based on the recovery of the Z-Val-Phe-hydrolyzing activity. (C) SDS-
PAGE analysis of samples of whole rat MAB  perfusate (lane 1), material loaded onto
the  MonoQ column (lane 2) and MonoQ-puriﬁed Ang-(1-9)-forming enzyme before
(lane 3) and after removal of contaminating kininase by arginine-Sepharose chro-
matography (lane 4) on 15% polyacrylamide gel stained with coomassie blue; theH.J.V. Pereira et al. / 
27] and mesentery (Fig. 2) indicated full identity between all 1184
ucleotides that could be actually compared except a C876T silent
utation for Ile289 of the preproenzyme. Sequence data of the
DNA for rat mesenteric CPA1, shown in Fig. 2, lack information
orresponding to the segment from T650 to A723 of the archetypal
ancreatic preproCPA1, a region that spans 46% of exon 6 and
3% of exon 7. This shortcoming occurred merely for technical
easons, namely the low resolution of the sequencing procedure
bserved for that region; in spite of this, the data presented in
ig. 2 indicate that all exons of the rat pancreatic CPA1 [4] are
ound in our sequence, suggesting that both the pancreatic and
esenteric forms of rat CPA1 followed identical splicing proﬁle.
.1.2. Isolation of the rat MAB  perfusate CPA2
As shown in Fig. 3, a second CPA was isolated from the
at MAB  perfusate using a puriﬁcation protocol resembling that
escribed above for the Ang-(1-7)-forming CPA. A fresh P3 prepa-
ation, obtained as previously described [25], was  used as the
tarting material for the puriﬁcation procedure, which yielded a
ingle peak of CPA activity upon MonoQ anion-exchange chro-
atography (Fig. 3A). Since we observed CPB activity overlapping
he CPA activity peak in the MonoQ chromatography fractions,
he pooled material from the CPA-rich fractions was applied
o an arginine-Sepharose column for removal of this contam-
nant enzyme (Fig. 3B), a process monitored by following the
istribution of kininase activity along the eluting fractions. The
esulting puriﬁed CPA preparation has two components of approx-
mately 33.5 kDa and 115 kDa, as shown by SDS-PAGE (Fig. 3C,
ane 4), whose identities were established as follows. MS/MS
eptide mass ﬁngerprint of in-gel tryptic digest of the excised
3.5 kDa molecular mass protein spot from the SDS-PAGE identi-
ed seven peptides, shown in Fig. 4, which match the indicated
egments of the described rat pancreatic CPA2 sequence [10].
ikewise, MS/MS  peptide mass ﬁngerprint of in-gel tryptic digest
f the excised high molecular mass protein spot from the SDS-
AGE identiﬁed the peptides KGTDFQLNQLQGK, HTTIFEVLPQK,
SDSSINWNNLKGK, GDVAFVK, HQTVLENTNGK and DLLFRDDTK,
hich match the fragments 122–134, 226–236, 455–468, 547–553,
54–564 and 647–655, respectively, of the mature rat transfer-
in sequence (NCBI GenBank ID: BAA07548.1). As judged by the
DS-PAGE data of Fig. 3C, lane 4, transferrin is the only contam-
nant of our CPA2 preparation obtained from rat MAB  perfusate;
o attempts were made to rid the CPA2 preparation of this prote-
lytically inactive substance for the sake of recovery of CPA activity
uring the puriﬁcation process. The ﬁnding of a functional CPA2
n the rat MAB  perfusate, an enzyme which structurally resembles
hat isolated from pancreas [10], led us to investigate the presence
f the respective RNA message in the rat mesentery as an evidence
f the local synthesis of the enzyme. The complete sequence of the
loned cDNA for the rat mesenteric preproCPA2 was obtained as
escribed in Section 2.6.2, which turned out to be identical with that
f rat pancreas [10] except for the base changes G177T, C439A and
1148G. The latter two changes introduced the mutations L147I
nd A383G (preproCPA2 numbering), indicating the polymorphic
ature of this enzyme.
.2. Proteolytic processing of Ang peptides by CPA1 and CPA2:
elative rates of degradation of Ang I, Ang-(1-9), Ang II and
ng-(1-12)
Whereas the rat MAB  perfusate CPA1 was isolated as an Ang-
1-7)-forming enzyme using Ang II as the substrate for monitoring
he activity during the chromatographic puriﬁcation of the enzyme
Fig. 1A), the isolation of the CPA2 was attained by measuring its
ctivity toward Z-Val-Phe, a general purpose substrate for CPAs
Fig. 3A and B). In spite of this, CPA2 was later shown capablepositions of Mr  standard proteins (14.4–116 kDa) are indicated on the left side of
the  gel. The identiﬁcation of the major Ang-(1-9)-forming enzyme of the rat MAB
perfusate as CPA2 was done as shown in Fig. 4.
of hydrolyzing some Ang peptides with substrate speciﬁcity
suggestive that differences between rat MAB  CPA1 and CPA2 go
beyond those observed during their isolations. These enzymes
differentially process peptide components of the RAS such as Ang
I, Ang II, Ang-(1-9) and Ang-(1-12), as shown in Figs. 5 and 6. For
the sake of comparison between enzyme preference for different
substrates, hydrolysis of each of these peptides was determined
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Met Arg  Leu Thr Leu Leu Leu Ala Ala Le u Leu Gly Tyr Ile T yr C ys G ln  Glu  Thr  Phe 20 
ATG AGG TTG ACC CTG TTA TTG GCT GCC CTA CTT GGG TAT ATC TAC TGT CAA GAA ACG TTT 60 '
Val Gly  Asp Gln Val Leu Glu Ile Ile Pr o Ser His Glu Glu G ln I le A rg  Thr  Leu  Leu 40 
GTG GGA GAT CAA GTT CTT GAG ATC ATC CCA AGT CAT GAA GAG CAA ATT AGA ACT CTG CTG 12 0' 
Gln Leu  Glu Ala Glu Asp His Leu Glu Le u Asp Phe Trp Lys S er P ro T hr  Ile  Pro  Gly 60 
CAA TTG GAG GCT GAA GAG CAT CTC GAG CTT GAT TTT TGG AAA TCA CCC ACC ATC CCG  GGG 18 0' 
Glu Thr  Val His Val Arg Val Pro Phe Al a Ser Ile Gln Ala V al L ys V al  Phe  Leu  Glu 80 
GAG ACA GTC CAC GTT CGA GTC CCT TTT GCT AGC ATC CAG GCT GTC AAG GTT TTC TTG GAG 24 0' 
Ser Gln  Gly Ile Asp Tyr Ser Ile Met Il e Glu Asp Val Gln V al L eu L eu  Asp  Gln  Glu 10 0
TCC CAG GGG ATC GAT TAT TCC ATC ATG ATC GAA GAT GTT CAA GTT CTG TTG GAT CAA GAG 30 0' 
Arg Glu  Glu Met Leu Phe Asn Gln Gln Ar g Glu Arg Gly Gly A sn P he A sn  Phe  Glu  Ala 12 0
CGG GAA GAA ATG CTA TTC AAC CAG CAA AGA GAG CGT GGT GGG AAC TTC AAC TTT GAG GCC 36 0' 
Tyr His  Thr Leu Glu Glu Ile Tyr Gln Gl u Met Asp Asn Leu V al A la G lu  Asn  Pro  Gly 14 0
TAC CAT ACC CTG GAA GAG ATT TAC CAA GAA ATG GAT AAC CTC GTG GCT GAG AAC CCC GGT 42 0' 
Leu Val  Ser Lys Val Asn Leu Gly Ser Se r Phe Glu Asn Arg P ro M et A sn  Val  Leu  Lys 16 0
CTA GTG AGC AAA GTG AAT CTC GGT TCA TCT TTT GAA AAT CGG CCC ATG AAT GTG CTC AAG 48 0' 
Phe Ser  Thr Gly Gly Asp Lys Pro Ala Il e Trp Leu Asp Ala G ly I le H is  Ala  Arg  Glu  18 0
TTC AGC ACC GGA GGA GAC AAG CCA GCC ATC TGG CTT GAT GCG GGG ATC CAT GCT CGA GAG 54 0' 
Trp Val  Thr Gln Ala Thr Ala Leu Trp Th r Ala Asn Lys Ile A la S er A sp  Tyr  Gly  Thr 20 0
TGG GTT ACA CAA GCT ACT GCA CTG TGG ACA GCA AAC AAG ATT GCT TCT GAT TAT GGA ACT 60 0' 
Asp Pro  Ala Ile Thr Ser Leu Leu Asn Th r Leu Asp Ile Phe L eu L eu P ro  Val  Thr  Asn 22 0
GAT CCA GCC ATC ACG TCT CTT CTT AAT ACT CTG GAT ATC TTC CTG CTG CCT GTC ACC AAT 66 0' 
Pro Asp  Gly Tyr Val Phe Ser Gln Thr Th r Asn Arg Met Trp A rg L ys T hr  Arg  Ser  Lys 24 0
CCC GAT GGA TAT GTG TTC TCC CAA ACC ACC AAT CGA ATG TGG AGA AAG ACC CGT TCT AAA 72 0' 
Arg Ser  Gly Ser Gly Cys Val Gly Val As p Pro As n Arg Asn T rp A sp A la  Asn  Phe  Gly 26 0
AGG TCA GGA AGC GGC TGT GTC GGT GTG GAT CCT AAT CGG AAC TGG GAT GCA AAT TTC GGA 78 0' 
Gly Pro  Gly Ala Ser Ser Ser Pro Cys Se r Asp Ser Tyr His G ly P ro L ys  Pro  Asn  Ser 28 0
GGA CCT GGA GCC AGT AGC AGC CCT TGC TCT GAC TCA TAC CAC GGA CCC AAG CCC AAC TCT 84 0' 
Glu Val  Glu Val Lys Ser Ile Val Asp Ph e Ile Lys Ser His G ly L ys Val  Lys  Ala  Phe 30 0
GAA GTT GAA GTG AAA TCC ATA GTG GAC TTC ATC AAG AGC CAC GGG AAA GTC AAA GCT TTT 90 0' 
Ile Thr  Leu His Ser Tyr Ser Gln Leu Le u Met Phe Pro Tyr G ly T yr L ys  Cys  Thr  Lys 32 0
ATT ACC CTT CAC AGC TAT TCC CAA CTG CTT ATG TTC CCC TAT GGC TAT AAA TGT ACC AAG 96 0' 
Pro Asp  Asp Phe Asn Glu Leu Asp Glu Va l Ala Gln Lys Ala A la G ln A la  Leu  Lys  Arg  34 0
CCA GAT GAC TTT AAT GAG CTG GAT GAA GTG GCC CAG AAG GCT GCC CAG GCT TTG AAA AGA 10 20' 
Leu His  Gly Thr Ser Tyr Lys Val Gly Pr o Ile Cys Ser Val I le T yr G ln  Ala  Ser  Gly 36 0
CTG CAC GGC ACC AGT TAT AAA GTG GGA CCC ATC TGT TCT GTC ATC TAC CAG GCG AGT GGT 10 80' 
Gly Ser  Ile Asp Trp Ala Tyr Asp Leu Gl y Ile Lys Ty r Ser P he A la P he  Glu  Leu  Arg  38 0
GGA AGC ATC GAC TGG GCT TAC GAC CTT GGC ATC AAA TAC TCA TTT GCC TTT GAA CTG AGG 11 40' 
Asp Thr  Ala Phe Tyr Gly Phe Leu Leu Pr o Ala Lys Gln Ile L eu P ro T hr  Ala  Glu  Glu  40 0
GAC ACA GCT TTC TAT GGC TTC CTC CTG CCA GCC AAG CAG ATC TTG CCG ACA GCA GAA GAG 12 00' 
Thr Trp  Leu Gly Leu Lys Thr Ile Met Gl u His Val Arg Asp H is P ro T yr  stop 417 
ACC TGG CTT GGC CTG AAG ACC ATC ATG GAG CAC GTA CGA GAC CAC CCC TAT TAG 125 4' 
Fig. 4. Nucleotide sequence of the cDNA encoding the rat mesenteric preproCPA2 and amino acid sequences of peptides derived from a major Ang-(1-9)-forming carboxypep-
tidase  of the rat MAB  perfusate. The sequences of the rat pancreatic preproCPA2 cDNA [10] (nucleotides 1–1254, primed numerals) and of the deduced amino acid sequence
for  the rat pancreatic preproCPA2 [10] (residues 1–417; NCBI GenBank ID: NP 001013101.2) are shown for comparison. Sequence identity between the two polynucleotide
chains  is indicated by underlined bases in the pancreatic preproCPA2 cDNA sequence. The base changes G177T, C439A and C1148G are the only differences observed between
the  two sequences, introducing the mutations L147I and A383G in the protein (preproCPA2 numbering). The tryptic fragments Glu180-Lys193, Ser286-Lys296, Arg340-Lys347,
T  resid
b chara
u
C
c
r
C
i
a
o
iyr373-Arg380, Asp381-Lys392, Gln393-Lys406 and Thr407-Arg413, indicated by boldface
y  in-gel digestion of a major Ang-(1-9)-forming CPA of the rat MAB  perfusate and 
sing a ﬁxed amount of either enzyme (0.41 mU  CPA1 and 1.02 mU
PA2, based on Z-Val-Phe hydrolysis), chosen so as to limit the
leavage of the substrate that was most rapidly degraded by the
espective enzyme to about 80% of its initial concentration. Rat
PA1 is remarkable in which, under the assay conditions described
n Fig. 5A, it is capable of generating Ang-(1-7) by a stepwise mech-
nism involving the sequential removal of the C-terminal residue
f the intermediate products Ang-(1-9) and Ang II. This mechanism
s rather corroborated by the results of the direct action of ratues within the amino acid sequence of the pancreatic preproCPA2, were generated
cterized by de novo peptide sequencing via tandem mass spectrometry.
CPA1 on the substrates Ang II and Ang-(1-9), shown in Fig. 5B and
C, respectively. Moreover, the accumulation of the intermediate
Ang-(1-9) during the conversion of Ang I to Ang-(1-7) suggests that
the cleavage of the C-terminal His residue of Ang-(1-9) may  be the
limiting step in the process. On the other hand, rat CPA2 generates
only Ang-(1-9) upon incubation with Ang I (Fig. 6A) and, under the
reaction conditions described in Fig. 6B and C, has a negligible, if
any, action on Ang II and Ang-(1-9), respectively. In contrast to rat
CPA1, CPA2 efﬁciently generates Ang I from Ang-(1-12); although
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Fig. 5. Cleavage of angiotensin peptides by CPA1 puriﬁed from rat MAB  perfusate.
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Fig. 6. Cleavage of angiotensin peptides by CPA2 puriﬁed from rat MAB  perfusate.
Ang I, Ang II and Ang-(1-9) (0.25 mM each; panels A-C) and Ang-(1-12) (0.2 mM;
panel D) were incubated at 37 ◦C for 30 min with 1.0 mU of CPA2 (Z-Val-Phe units)
and  the fragments formed identiﬁed by reversed phase HPLC. Note that the fragmentng I, Ang II and Ang-(1-9) (0.25 mM each; panels A–C) and Ang-(1-12) (0.2 mM;
anel D) were incubated at 37 ◦C for 30 min  with 0.4 mU of CPA1 (Z-Val-Phe units)
nd  the fragments formed identiﬁed by reversed phase HPLC.
his latter enzyme can further hydrolyze Ang I to Ang-(1-9), as
een in Fig. 6A, Ang I nevertheless accumulates in the reaction
edium (Fig. 6D). The CPA2-catalyzed conversion of Ang-(1-12)
o Ang I proceeds through stepwise cleavage of C-terminal Tyr and
eu residues, as inferred from amino acid analysis of the respective
eaction mixture (data not shown).
All reactions mediated by both rat MAB  CPA1 and CPA2, shown
n Figs. 5 and 6, were fully inhibited by 10 M PCI or 1.0 mM 1,10-
henanthroline but not by 20 M soybean trypsin inhibitor (data
ot shown).
.3. Kinetic analysis for the Ang II cleavage reactionThe inherent difﬁculties of measuring initial velocities for
nzyme reactions in which products are further processed pre-
ented us from determining kinetic constants for CPA-catalyzed
ydrolysis of all Ang peptides tested except Ang II. The results ofAng-(1-11) coelutes with substrate Ang-(1-12) under the analytical conditions used.
Equimolar amounts of free Tyr and Leu were released from the substrate Ang-(1-12)
upon incubation with CPA2 (measured by amino acid analysis; not shown).
Fig. 7 indicate that the catalytic efﬁciency for the CPA1-catalyzed
Ang II to Ang-(1-7) conversion reaction is two orders of magnitude
higher than that mediated by CPA2, as judged by the kcat/Km values
for the respective reactions. It should be noted that the rather small
catalytic efﬁciency of CPA2 for the Ang II to Ang-(1-7) conversion
reaction compelled the use of higher enzyme concentration, longer
incubation times and larger reaction volumes, compared with the
conditions described in Fig. 6B, in order to yield reliable initial
velocity measurements for kinetic analysis presented in Fig. 7.
3.4. Rat CPA1 and CPA2 mRNAs have peculiar tissue-speciﬁc
expression
The expression of CPA1 and CPA2 mRNAs in some rat tis-
sues was  investigated by RT-PCR using speciﬁc CPA1 and CPA2
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Fig. 7. Determination of catalytic constants for the hydrolysis of Ang II catalyzed by
CPA1 and CPA2 from rat MAB  perfusate. The effect of Ang II concentration on the rate
of Ang-(1-7) formation by each enzyme was measured, in duplicate, as described in
Section 2.3.1. The constants Km and kcat for each indicated reaction were derived by
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Fig. 8. Detection of mRNAs for rat CPA1 and CPA2 in different tissues using RT-PCR.
Each lane of the ethidium bromide-stained agarose gels shows the RT-PCR products
derived from total RNA for the indicated rat tissues using speciﬁc primers for CPA1
(panel A, top; amplicon size 1260 bp), CPA2 (panel B, top; amplicon size 1254 bp) and
-actin, a control for matching the RT-PCR processes for the different total mRNA
preparations (panels A and B, bottom; 351 bp). The primers used in the reactions
are shown in Table 1. The expression level of mRNAs for CPA1 and CPA2 in the
various tissues was estimated by densitometric scanning of the gels, normalized
to  the corresponding -actin product, and expressed as CPA/-actin ratio in theon-linear regression analysis of data plotted according to the Michaelis–Menten
quation. The constants kcat and kcat/Km are expressed on the basis of enzyme mil-
iunits determined for the hydrolysis of Z-Val-Phe by the respective enzyme.
rimers described in Table 1 and total RNA extracted from the
ndicated tissues (Fig. 8). The PCR-ampliﬁed DNA fragments have
izes corresponding to those previously described for rat pancre-
tic preproCPA1, 1260 bp [27], and preproCPA2, 1254 bp [10]. No
CR products were detected when sterile water was  a substitute
or the respective cDNA in the reaction (not shown). CPA1 mRNA
as highly expressed in mesentery, pancreas, liver, lung and heart
ut was below detection level in kidney, aorta and carotid artery.
 marked expression for CPA2 mRNA was detected in mesentery,
iver, lung, pancreas, heart and carotid artery, but an expression
ust above detection level in kidney and aorta.
. Discussion
The rat MAB  perfusate contains different proteases [22], among
hich carboxypeptidases that give rise to local bradykinin- and
ng-processing pathways [23,25]. Two of the rat MAB  perfusate
arboxypeptidases that act on Ang peptides were puriﬁed and
tructurally characterized in the present work, revealing that the
esenteric vasculature produces CPA1 and CPA2 that are identi-
al with their pancreatic counterparts as shown in Figs. 2 and 4,
espectively. Although both CPA1 and CPA2 are prototypical pan-
reatic enzymes with digestive functions [33], their presence in the
esenteric vasculature suggests that they may  constitute, along
ith other resident enzymes, local metabolic pathways for pro-
essing vasoactive peptides. Traditionally, only mast cell CPA and
lasma CPU have been considered as regulatory enzymes within
he M14  family of metallocarboxypeptidases [33]. More recently it
as proposed that CPA6, an extracellular matrix protease secreted
n some areas of human and mouse brains, plays a role in the
egulation of neuropeptides [17]; also, we have shown that the
ajor kininase of the rat MAB  perfusate is identical with rat CPB1column chart (C). Tissues are indicated as follows: Ki, kidney; Pa, pancreas; Li, liver;
Lu,  lung; Me, mesentery; He, heart; Ao, aorta; Ca, carotid artery.
[23], another prototypical pancreatic metallopeptidase. Thus, our
present demonstration that rat MAB  CPA1 and CPA2 are capable
of processing Ang peptides extends the current evidence of the
participation of metallocarboxypeptidases in regulatory pathways.
The peculiar proteolytic proﬁles displayed by CPA1 and CPA2
toward Ang peptides probably reﬂect the proposed evolution-
ary events that have allowed these enzymes to diverge from one
another with respect to substrate speciﬁcity, resulting in over-
lapping and complementary preferences [10]. Thus, Ang I was
efﬁciently acted upon by CPA1, forming Ang-(1-7) by a three-step
pathway with Ang-(1-9) and Ang II as intermediates (Fig. 5A); con-
ﬁrmatory evidence of this sequential mode of action of CPA1 has
been provided by the formation of the end-product Ang-(1-7) in
analogous reactions when either Ang-(1-9) or Ang II, the intermedi-
ates in the conversion of Ang I to Ang-(1-7), were used as substrate
for the enzyme (Fig. 5B and C). On the other hand, only Ang-(1-9)
was released upon incubation of Ang I with CPA2 (Fig. 6A); in agree-
ment with this result, the substrates Ang II and Ang-(1-9) were
negligibly hydrolyzed by CPA2 under the conditions described in
Fig. 6B and C. Comparison of the catalytic efﬁciencies of the CPA1-
and CPA2-mediated conversions of Ang II to Ang-(1-7) indicates a
value approximately 200-fold higher for the former enzyme (Fig. 7),
consistent with the results of Ang II cleavage by these enzymes
shown in Figs. 5 and 6B; such a discrepancy between kinetic param-
eters of CPA1 and CPA2 toward Ang II is signiﬁcantly larger than
those observed for synthetic substrates having carboxyl-terminal
Phe residue [10], the same terminal residue of Ang II. It should also
be noted here that the Km value for the CPA1-catalyzed conver-
sion of Ang II to Ang-(1-7), as determined in Fig. 7, is of the same
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rder of magnitude as that of the analogous reaction catalyzed by
CE2 [28], a carboxypeptidase for which there is compelling evi-
ence of participation in the RAS [34]; thus, the binding afﬁnity
f rat CPA1 for Ang II seems compatible with the participation
f this enzyme in the formation of Ang-(1-7) under physiological
onditions. However, the contribution of CPA1 to the in vivo gen-
ration of Ang-(1-7) in the rat mesenteric vascular bed is likely to
epend on factors beyond that of the enzyme afﬁnity for Ang II,
mong which the actual CPA1 activity and the presence of circulat-
ng carboxypeptidase inhibitors. Assuming that CPA1 is the major
nzyme responsible for the Ang II to Ang-(1-7) conversion reac-
ion in the rat MAB  perfusate, as inferred from the present work
Figs. 1A and 5B), a rat MAB  secretes on average an amount of this
nzyme, per second, capable of processing over 50 pmol Ang II per
in  under conditions prevailing in the in vitro enzyme assay [25];
lthough such CPA1 activity is large enough to metabolize signif-
cant amounts of Ang II, it should be borne in mind that protease
nhibitors and degradation of the enzyme may  check the enzyme
ctivity under in vivo conditions. Thus, the possible involvement of
PA1 in the mesenteric vascular bed RAS and the relative contri-
ution of this enzyme to the local generation of Ang-(1-7) need to
e established. Another striking difference between the proteolytic
peciﬁcities of rat MAB  CPA1 and CPA2 was revealed using Ang-(1-
2) as a substrate; as shown in Figs. 5D and 6D,  Ang-(1-12) was  a
ar better substrate for CPA2 than for CPA1, notwithstanding their
early identical efﬁciencies to cleave the carboxyl-terminal Tyr
esidue from a model synthetic peptide [10]. These ﬁndings regard-
ng substrate preferences of CPA1 and CPA2 suggest that structural
eatures that determine substrate speciﬁcity of these enzymes go
eyond the terminal residue. On account of the in vitro capability of
PA1 and CPA2 to form biologically active Ang I-derived peptides,
amely, Ang-(1-9), Ang II and Ang-(1-7), as observed in Figs. 5 and 6,
hese enzymes can, therefore, be regarded as potential regulators
f local RAS in the rat mesenteric vasculature. Among the peptides
rocessed by rat MAB  CPA1 and CPA2, Ang II has been traditionally
iewed as the central effector molecule of the RAS, whose actions
n the cardiovascular system and tissue proliferation are mediated
ainly by the Ang type-1 (AT1) receptor and also by AT2 recep-
or, which opposes at least some of the effects of AT1 stimulation
2,7]. Ang-(1-9) is an endogenous ACE inhibitor [13,29] and precur-
or of Ang-(1-7) [16,28], while this latter heptapeptide participates
n distinct regulatory processes of the cardiovascular function by
timulating a receptor of its own, the Mas  receptor [7]. The abil-
ty of CPA2 and, to a much lesser extent of CPA1, to generate Ang
 from Ang-(1-12), as shown in Figs. 5D and 6D,  is remarkable in
hat it creates a pathway for utilization of this recently identi-
ed putative component of the RAS. Ang-(1-12) is thought to be
irectly derived from angiotensinogen by a renin-independent pro-
ess, being a highly abundant Ang peptide in several rat tissues [20].
he processing of this dodecapeptide into shorter Ang peptides has
een demonstrated under different experimental conditions, sug-
esting the participation of ACE [1,31],  chymase [26] and neprilysin
31] in the formation of Ang I, Ang II and Ang-(1-7), respectively.
ng-(1-12) is found in its highest levels in extracts of rat intestine
20], a tissue whose vessels can secrete CPA2, an efﬁcient in vitro
ng-(1-12)-metabolizing enzyme (Fig. 6D); any functional correla-
ion between CPA2 and Ang-(1-12) in the rat MAB and other organs
emains to be established, particularly in view of the demonstra-
ion that the routes for Ang-(1-12) metabolism in plasma and tissue
xtracts correlate with their contents of ACE and neprilysin [3].
In addition to purifying and characterizing the CPA1 and CPA2
rom rat MAB  in this work, we also investigated the expression of
he respective mRNAs in some other rat tissues. Gene transcripts
or CPA1 and CPA2 of about 1.26 kb were detected at different levels
n some of the rat tissues investigated (Fig. 8), indicating that a sec-
etable form of these enzymes, of the same size of their respectivees 33 (2012) 67–76 75
pancreatic counterparts, are expressed in various tissues. In a previ-
ous report [21], it was  described that a single CPA1 mRNA, identical
with that of the pancreatic CPA1, is also expressed in rat brain, heart,
stomach and intestine at low levels, suggesting a selective expres-
sion of the enzyme in restricted cell populations of these tissues.
On the other hand, the CPA2 mRNA was reported to be expressed in
rat brain, lung and testis as a shortened CPA2 transcript, produced
presumably by alternative splicing of the CPA2 pro-mRNA, that
differs from the full-length pancreatic transcript by deletion of a
sequence that encodes the signal and activation peptides of the
pancreatic preproenzyme; as predicted by the sequence of this
shortened mRNA, rat brain CPA activity was shown to be associated
with a cytosolic CPA2 lacking the signal and activation peptides,
whose enzymological and inhibitory properties differ from those
of the full-length CPA2. The display of such an altered enzyme
activity associated with a particular subcellular localization of this
shortened CPA2 has led to the suggestion that this enzyme plays a
role distinct from that fulﬁlled by CPA2 in protein digestion [21].
It is worth stressing that, in the present work, we detected only an
mRNA for CPA of about 1.26 kb in the rat lung (Fig. 8), correspond-
ing to the full-length pancreatic enzyme. Since the oligonucleotide
primers we used for detection of the cDNA encoding the rat CPA2
(Table 1) would not amplify the cDNA of the shortened rat CPA2
described by Normant et al. [21], the possibility remains that rat
lung expresses both the cytosolic and secreted isoforms of CPA2.
Based on the extrapancreatic distribution of the rat CPA1
and CPA2 (Fig. 8) and on the peculiar proteolytic speciﬁcities of
these enzymes (Figs. 5 and 6), we suggest that, in spite of their
being structurally identical with the respective digestive pancreatic
counterparts, they may be directly involved with local processing
of Ang peptides and other so far unidentiﬁed peptides in the vascu-
lature of different tissues. Indeed, the suggestion that rat CPA1 and
CPA2 may  participate in the processing of Ang peptides ﬁnds sup-
port in an earlier report of the expressive production of Ang-(1-9) in
the rat kidney by an unspeciﬁed CPA-like enzyme that localizes to
the mesangial glomerular cells and adventitia of kidney blood ves-
sels [11]. From the functional standpoint, the contribution of CPA1
and CPA2 to the local metabolism of Ang peptides is likely to depend
on the repertoire of proteolytic enzymes of a particular tissue or,
else, on the suppression of competing pathways for the degradation
of a particular Ang peptide by therapeutic or endogenous inhibitors.
For instance, the major Ang I-derived metabolite formed by human
heart homogenate in the presence of interstitial ﬂuid was not Ang
II but Ang-(1-9), because the Ang II-forming enzymes chymase and
ACE were suppressed by endogenous inhibitors to which the car-
boxypeptidases of human heart were refractory [13].
In conclusion, we  hypothesize that rat CPA1 and CPA2, in addi-
tion to their well established function as digestive enzymes [33],
belong to the RAS for their possible participation in the circulating
and cellular network interconnected by enzyme-catalyzed reac-
tions leading to the formation of Ang II and other Ang I-derived
biologically active peptides.
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